人脐带间充质干细胞治疗失代偿期肝硬化疗效及安全性的Meta分析OA
Meta-analysis on the efficacy and safety of human umbilical cord mesenchymal stem cells in treating decompensated liver cirrhosis
目的 系统评价人脐带间充质干细胞(human umbilical cord mesenchymal stem cells,hUC-MSCs)对失代偿期肝硬化的临床疗效及安全性.方法 检索多个数据库中有关hUC-MSCs治疗失代偿期肝硬化的随机对照试验,最终纳入13项临床研究,涉及1024例患者.对纳入文献进行Meta分析.结果 Meta分析结果显示,与对照组比较,移植hUC-MSCs可改善失代偿期肝硬化患者多项肝功能指标、腹水及血氨水平,但对总胆红素改善不明显,且存在一定程度的不良反应.结论 hUC-MSCs可有效改善失代偿期肝硬化患者多项关键临床指标,具有临床应用价值.
Objective To systematically assess the efficacy and safety of human umbilical cord mesenchymal stem cells(hUC-MSCs)transplantation in the management of decompensated liver cirrhosis.Methods Randomized controlled trials regarding hUC-MSCs for decompensated liver cirrhosis were electronically retrieved from databases.A total of 13 clinical studies involving 1024 patients were ultimately included.Meta-analysis were conducted on the enrolled literature.Results Meta-analysis results demonstrated that compared with control group,transplantation of hUC-MSCs improved multiple liver function parameters,ascites,and serum ammonia levels in patients with decompensated cirrhosis,but showed no significant improvement in total bilirubin levels and was associated with certain adverse reactions.Conclusion hUC-MSCs effectively improve multiple key clinical indicators in patients with decompensated cirrhosis,demonstrating clinical applicability.
梁彦;邓紫莹;刘序友
暨南大学附属广州红十字会医院消化内科,广东 广州 510220暨南大学附属广州红十字会医院消化内科,广东 广州 510220暨南大学附属广州红十字会医院消化内科,广东 广州 510220
医药卫生
脐带间充质干细胞肝硬化失代偿期Meta分析
Umbilical cord mesenchymal stem cellsCirrhosisDecompensatedMeta-analysis
《中国现代医生》 2026 (14)
41-46,6
评论